TWI505828B - 新穎醫藥組成物 - Google Patents

新穎醫藥組成物 Download PDF

Info

Publication number
TWI505828B
TWI505828B TW100146692A TW100146692A TWI505828B TW I505828 B TWI505828 B TW I505828B TW 100146692 A TW100146692 A TW 100146692A TW 100146692 A TW100146692 A TW 100146692A TW I505828 B TWI505828 B TW I505828B
Authority
TW
Taiwan
Prior art keywords
tablet
lozenge
drug
pharmaceutical
dimethyl
Prior art date
Application number
TW100146692A
Other languages
English (en)
Chinese (zh)
Other versions
TW201249441A (en
Inventor
道格拉斯 狄馬林
諾迪普 李
法蘭斯科 軒歷基斯
王立弘
Original Assignee
葛蘭素史克智慧財產(第二)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI505828(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 葛蘭素史克智慧財產(第二)有限公司 filed Critical 葛蘭素史克智慧財產(第二)有限公司
Publication of TW201249441A publication Critical patent/TW201249441A/zh
Application granted granted Critical
Publication of TWI505828B publication Critical patent/TWI505828B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW100146692A 2010-12-20 2011-12-16 新穎醫藥組成物 TWI505828B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20

Publications (2)

Publication Number Publication Date
TW201249441A TW201249441A (en) 2012-12-16
TWI505828B true TWI505828B (zh) 2015-11-01

Family

ID=46314827

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100146692A TWI505828B (zh) 2010-12-20 2011-12-16 新穎醫藥組成物

Country Status (38)

Country Link
US (5) US20130266649A1 (https=)
EP (4) EP2654736B1 (https=)
JP (2) JP6126014B2 (https=)
KR (1) KR101911109B1 (https=)
CN (1) CN103998041B (https=)
AR (2) AR084102A1 (https=)
AU (1) AU2011349422B2 (https=)
BR (1) BR112013015602B1 (https=)
CA (1) CA2822701C (https=)
CL (1) CL2013001779A1 (https=)
CR (1) CR20130352A (https=)
CY (1) CY1123376T1 (https=)
DK (3) DK4159205T3 (https=)
DO (1) DOP2013000138A (https=)
EA (1) EA025198B1 (https=)
ES (3) ES2985024T3 (https=)
FI (2) FI4159204T3 (https=)
HR (3) HRP20201409T1 (https=)
HU (3) HUE050788T2 (https=)
IL (1) IL226855A (https=)
JO (1) JO3594B1 (https=)
LT (3) LT4159205T (https=)
MA (1) MA34883B1 (https=)
MX (1) MX2013007073A (https=)
MY (1) MY170501A (https=)
NZ (1) NZ612157A (https=)
PE (1) PE20140040A1 (https=)
PH (1) PH12013501209A1 (https=)
PL (3) PL4159205T3 (https=)
PT (3) PT2654736T (https=)
RS (2) RS65497B1 (https=)
SG (1) SG191054A1 (https=)
SI (3) SI2654736T1 (https=)
TW (1) TWI505828B (https=)
UA (1) UA113158C2 (https=)
UY (1) UY33818A (https=)
WO (1) WO2012088033A2 (https=)
ZA (1) ZA201304189B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
AU2013352369B2 (en) * 2012-11-30 2016-07-28 Novartis Ag. Novel pharmaceutical composition
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1(2H)-基苯基乙酰胺的衍生物及其应用
CN104918937B (zh) * 2013-12-06 2016-09-14 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
TWI777658B (zh) 2016-08-10 2022-09-11 瑞士商赫孚孟拉羅股份公司 包含Akt蛋白質激酶抑制劑之醫藥組合物
RU2627692C1 (ru) * 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
JP2019535696A (ja) * 2016-11-25 2019-12-12 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. ピリドン誘導体の医薬組成物およびその製造方法
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CN114340670B (zh) 2019-07-11 2026-02-17 普拉克西斯精密药物股份有限公司 T-型钙通道调节剂的制剂及其使用方法
EP4725489A2 (en) 2019-08-02 2026-04-15 OneHealthCompany, Inc. Treatment of canine cancers
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer
WO2024171019A1 (en) * 2023-02-13 2024-08-22 Alembic Pharmaceuticals Limited Pharmaceutical composition of trametinib and process of preparation thereof
WO2025132408A2 (en) 2023-12-21 2025-06-26 Synthon B.V. Solvates of trametinib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254131A1 (en) * 2006-10-13 2008-10-16 Sunil Vandse Controlled-release galantamine formulations
US20100240613A1 (en) * 2004-06-11 2010-09-23 Japan Tobacco Inc. Pyrimidine compound and medical use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
AU2005252110B2 (en) * 2004-06-11 2008-09-04 Shionogi & Co., Ltd. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer
CA2668724A1 (en) * 2006-11-09 2008-05-22 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
UA99731C2 (ru) * 2007-07-30 2012-09-25 Ардеа Биосайенсис, Инк Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
BRPI0817946A2 (pt) * 2007-09-25 2015-05-05 Teva Pharma Composições de imatinibe estável
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2392576B1 (en) * 2008-07-08 2016-02-17 Beta Pharma, Inc. Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof
CN102762098B (zh) 2009-09-23 2015-10-14 葛兰素史密斯克莱有限责任公司 组合
AU2010298277B2 (en) 2009-09-23 2014-07-03 Novartis Ag Combination
MX2012003779A (es) * 2009-09-28 2012-06-01 Glaxosmithkline Llc Combinacion.
US8703781B2 (en) * 2009-10-16 2014-04-22 Glaxosmithkline Llc Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
MX2012005758A (es) 2009-11-17 2012-06-19 Glaxosmithkline Llc Combinacion.
EP2608790A4 (en) 2010-08-26 2014-04-02 Glaxosmithkline Llc PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit
CZ2015278A3 (cs) 2015-04-24 2016-11-02 Zentiva, K.S. Krystalické formy trametinibu

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240613A1 (en) * 2004-06-11 2010-09-23 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
US20080254131A1 (en) * 2006-10-13 2008-10-16 Sunil Vandse Controlled-release galantamine formulations

Also Published As

Publication number Publication date
DK4159204T3 (da) 2024-05-21
EP2654736B1 (en) 2020-07-01
CA2822701C (en) 2018-10-23
EP3808343A1 (en) 2021-04-21
CN103998041A (zh) 2014-08-20
FI4159205T3 (fi) 2024-04-23
ES2982775T3 (es) 2024-10-17
PT4159205T (pt) 2024-05-08
HRP20201409T1 (hr) 2020-11-27
ES2820536T3 (es) 2021-04-21
JP2014510704A (ja) 2014-05-01
US20140154316A1 (en) 2014-06-05
CL2013001779A1 (es) 2014-06-27
AR084102A1 (es) 2013-04-24
TW201249441A (en) 2012-12-16
LT4159205T (lt) 2024-05-10
SG191054A1 (en) 2013-08-30
MY170501A (en) 2019-08-08
EP4159204A1 (en) 2023-04-05
HUE066526T2 (hu) 2024-08-28
EP2654736A4 (en) 2015-04-22
US20140037726A1 (en) 2014-02-06
PT4159204T (pt) 2024-05-07
US20120183613A1 (en) 2012-07-19
SI4159204T1 (sl) 2024-06-28
ES2985024T3 (es) 2024-11-04
NZ612157A (en) 2015-05-29
CR20130352A (es) 2013-12-18
UY33818A (es) 2012-07-31
RS65496B1 (sr) 2024-06-28
US20140099365A1 (en) 2014-04-10
ZA201304189B (en) 2014-02-26
JP6126014B2 (ja) 2017-05-10
US9271941B2 (en) 2016-03-01
HUE066525T2 (hu) 2024-08-28
SI4159205T1 (sl) 2024-06-28
MA34883B1 (fr) 2014-02-01
FI4159204T3 (fi) 2024-04-22
PL4159205T3 (pl) 2024-06-24
AR122185A2 (es) 2022-08-24
HUE050788T2 (hu) 2021-01-28
EP4159204B1 (en) 2024-02-14
PL4159204T3 (pl) 2024-07-01
US9399021B2 (en) 2016-07-26
PE20140040A1 (es) 2014-02-26
PT2654736T (pt) 2020-09-24
US8580304B2 (en) 2013-11-12
BR112013015602B1 (pt) 2022-03-03
AU2011349422B2 (en) 2015-12-10
JO3594B1 (ar) 2020-07-05
PL2654736T3 (pl) 2020-12-14
DK4159205T3 (da) 2024-05-13
KR20130130028A (ko) 2013-11-29
SI2654736T1 (sl) 2020-10-30
US9155706B2 (en) 2015-10-13
EP4159205B1 (en) 2024-02-14
LT4159204T (lt) 2024-05-10
EA201390913A1 (ru) 2014-04-30
RS65497B1 (sr) 2024-06-28
EP2654736A2 (en) 2013-10-30
UA113158C2 (xx) 2016-12-26
CY1123376T1 (el) 2021-12-31
WO2012088033A3 (en) 2014-03-13
HRP20240563T1 (hr) 2024-08-16
AU2011349422A1 (en) 2013-05-02
CN103998041B (zh) 2016-08-17
JP2017137299A (ja) 2017-08-10
CA2822701A1 (en) 2012-06-28
DOP2013000138A (es) 2013-11-30
US20130266649A1 (en) 2013-10-10
LT2654736T (lt) 2020-09-25
WO2012088033A2 (en) 2012-06-28
BR112013015602A2 (pt) 2017-02-21
KR101911109B1 (ko) 2018-10-23
DK2654736T3 (da) 2020-09-14
MX2013007073A (es) 2013-09-26
EP4159205A1 (en) 2023-04-05
IL226855A (en) 2017-04-30
HRP20240564T1 (hr) 2024-09-27
PH12013501209A1 (en) 2013-07-29
EA025198B1 (ru) 2016-11-30

Similar Documents

Publication Publication Date Title
TWI505828B (zh) 新穎醫藥組成物
AU2013352369A1 (en) Novel pharmaceutical composition
KR20200024890A (ko) 신규한 약학적 조성물
HK40043030A (en) Novel pharmaceutical composition
HK40086707A (en) Novel pharmaceutical composition
HK40086707B (en) Novel pharmaceutical composition
HK40086699A (en) Novel pharmaceutical composition
HK40086699B (en) Novel pharmaceutical composition